Skip to main content

DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling



Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated with a lupus phenotype. It is unclear whether interferon signaling is sustained in DNASE1L3 deficiency in humans.


To explore interferon signaling in DNASE1L3 deficient patients. To depict the characteristic features of DNASE1L3 deficiencies in human.


We identified, characterized, and analyzed five new patients carrying biallelic DNASE1L3 variations. Whole or targeted exome and/or Sanger sequencing was performed to detect pathogenic variations in five juvenile systemic erythematosus lupus (jSLE) patients. We measured interferon-stimulated gene (ISG) expression in all patients. We performed a systematic review of all published cases available from its first description in 2011 to March 24th 2022.


We identified five new patients carrying biallelic DNASE1L3 pathogenic variations, including three previously unreported mutations. Contrary to canonical type I interferonopathies, we noticed a transient increase of ISGs in blood, which returned to normal with disease remission. Disease in one patient was characterized by lupus nephritis and skin lesions, while four others exhibited hypocomplementemic urticarial vasculitis syndrome. The fourth patient presented also with early-onset inflammatory bowel disease. Reviewing previous reports, we identified 35 additional patients with DNASE1L3 deficiency which was associated with a significant risk of lupus nephritis and a poor outcome together with the presence of anti-neutrophil cytoplasmic antibodies (ANCA). Lung lesions were reported in 6/35 patients.


DNASE1L3 deficiencies are associated with a broad phenotype including frequently lupus nephritis and hypocomplementemic urticarial vasculitis with positive ANCA and rarely, alveolar hemorrhages and inflammatory bowel disease. This report shows that interferon production is transient contrary to anomalies of intracellular DNA sensing and signaling observed in Aicardi-Goutières syndrome or STING-associated vasculitis in infancy (SAVI).

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Data Availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.


  1. Belot A, Rice GI, Omarjee SO, Rouchon Q, Smith EMD, Moreews M, et al. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol [Internet]. 2020 [cited 2020 Jan 16];0. Available from:

  2. Belot A, Cimaz R. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J. 2012;10:21.

    Article  Google Scholar 

  3. Omarjee O, Picard C, Frachette C, Moreews M, Rieux-Laucat F, Soulas-Sprauel P, et al. Monogenic lupus: dissecting heterogeneity. Autoimmun Rev. 2019;18:102361.

    Article  CAS  Google Scholar 

  4. Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011;43:127–31.

    Article  CAS  Google Scholar 

  5. An J, Briggs TA, Dumax-Vorzet A, Alarcón-Riquelme ME, Belot A, Beresford M, et al. Tartrate-resistant acid phosphatase deficiency in the predisposition to systemic lupus erythematosus. Arthritis Rheumatol Hoboken NJ. 2017;69:131–42.

    Article  CAS  Google Scholar 

  6. Crow YJ. Lupus: how much “complexity” is really (just) genetic heterogeneity? Arthritis Rheum. 2011;63:3661–4.

    Article  Google Scholar 

  7. Belot A, Kasher PR, Trotter EW, Foray A-P, Debaud A-L, Rice GI, et al. Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 2013;65:2161–71.

    Article  CAS  Google Scholar 

  8. Al-Mayouf SM, Sunker A, Abdwani R, Abrawi SA, Almurshedi F, Alhashmi N, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43:1186–8.

    Article  CAS  Google Scholar 

  9. Özçakar ZB, Foster J, Diaz-Horta O, Kasapcopur O, Fan Y-S, Yalçınkaya F, et al. DNASE1L3 mutations in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum. 2013;65:2183–9.

    Article  Google Scholar 

  10. Carbonella A, Mancano G, Gremese E, Alkuraya FS, Patel N, Gurrieri F, et al. An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. Lupus. 2017;26:768–72.

    Article  CAS  Google Scholar 

  11. Batu ED, Koşukcu C, Taşkıran E, Sahin S, Akman S, Sözeri B, et al. Whole exome sequencing in early-onset systemic lupus erythematosus. J Rheumatol. 2018;45:1671–9.

    Article  CAS  Google Scholar 

  12. Bruschi M, Bonanni A, Petretto A, Vaglio A, Pratesi F, Santucci L, et al. Neutrophil extracellular traps (NETs) profiles in patients with incident SLE and lupus nephritis. J Rheumatol. 2020;47:377–86.   

  13. Ranalli M, Passarelli C, Messia V, Pardeo M, Sacco E, Insalaco A, et al. Fri0554 Dnase1l3 variant in hypocomplementemic urticarial vasculitis syndrome identifies a different clinical phenotype. Ann Rheum Dis. BMJ Publishing Group Ltd; 2019;78:972–3.

  14. Yıldırım DG, Bakkaloğlu SA. Monogenic lupus caused by mutations in DNASE1L3: a rare cause of systemic lupus erythematosus in children. Scand J Immunol. 2022;e13162.

  15. Kisla Ekinci RM, Balci S, Ozcan D, Atmis B, Bisgin A. Monogenic lupus due to DNASE1L3 deficiency in a pediatric patient with urticarial rash, hypocomplementemia, pulmonary hemorrhage, and immune-complex glomerulonephritis. Eur J Med Genet. 2021;64:104262.

    Article  CAS  Google Scholar 

  16. Paç Kisaarslan A, Witzel M, Unal E, Rohlfs M, Akyildiz B, Dogan ME, et al. Refractory and fatal presentation of severe autoimmune hemolytic anemia in a child with the DNASE1L3 mutation complicated with an additional DOCK8 variant. J Pediatr Hematol Oncol. 2021;43:e452–6.

    Article  Google Scholar 

  17. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.

    Article  CAS  Google Scholar 

  18. Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716–30.

    Article  CAS  Google Scholar 

  19. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711–23.

    Article  CAS  Google Scholar 

  20. Crow YJ. Type I interferonopathies: Mendelian type I interferon up-regulation. Curr Opin Immunol. 2015;32C:7–12.

    Article  Google Scholar 

  21. Lee-Kirsch MA. The type I interferonopathies. Annu Rev Med. 2017;68:297–315.

    Article  CAS  Google Scholar 

  22. Lin B, Goldbach-Mansky R. Pathogenic insights from genetic causes of autoinflammatory inflammasomopathies and interferonopathies. J Allergy Clin Immunol. 2022;149:819–32.

    Article  CAS  Google Scholar 

  23. Aicardi J, Goutières F. Systemic lupus erythematosus or Aicardi-Goutières syndrome? Neuropediatrics. 2000;31:113.

    Article  CAS  Google Scholar 

  24. Rice GI, Forte GMA, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12:1159–69.

    Article  CAS  Google Scholar 

  25. Sisirak V, Sally B, D’Agati V, Martinez-Ortiz W, Özçakar ZB, David J, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 2016;166:88–101.

    Article  CAS  Google Scholar 

  26. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet. 2015;17:405–24.

    Google Scholar 

  27. Weill O, Decramer S, Malcus C, Kassai B, Rouvet I, Ginhoux T, et al. Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus. Joint Bone Spine. 2017;84:589–93.

  28. Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol. 1998;16:541–6.

    CAS  PubMed  Google Scholar 

  29. Rice GI, Forte G, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR a case-control study. Lancet Neurol. 2013;12:1159–69.

    Article  CAS  Google Scholar 

  30. Rodero MP, Tesser A, Bartok E, Rice GI, Della Mina E, Depp M, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun. 2017;19;8:2176.

  31. de Jesus AA, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2020;130:1669–82.

    Article  Google Scholar 

  32. Napirei M, Ludwig S, Mezrhab J, Klöckl T, Mannherz HG. Murine serum nucleases – contrasting effects of plasmin and heparin on the activities of DNase1 and DNase1-like 3 (DNase1l3). FEBS J. 2009;276:1059–73.

    Article  CAS  Google Scholar 

Download references


We thank the patients and their parents for participating in this study. This work is dedicated to Pr Rolando Cimaz who passed away last January 29th 2022.


Y.J.C. received a state subsidy managed by the National Research Agency (France) under the “Investments for the Future” (ANR-10-IAHU-01), and the MSDAvenir fund (DEVO-DECODE Project). A.B. was supported by the National Research Agency (France) (ANR-21-CE17-0064–01).

Author information

Authors and Affiliations



MT and AB made substantial contributions to the conception or design of the work. MT and AB drafted the manuscript. EL, CS, RP, ALM, MCM, VS, MD, AD, GN, AJ, LJ, JBG, EC, IR, DG, NF, GIR, GL, AL, PR, TW, SV, MP, YJC, TA, and AB were involved in the acquisition, analysis, or interpretation of data. All authors provided critical revision of the manuscript for important intellectual content.

Corresponding author

Correspondence to Alexandre Belot.

Ethics declarations

Ethics Approval

The study was approved by the Leeds (East) Research Ethics Committee (reference number 10/H1307/132) and the Medical Ethics Committee of Sud Est III (Lyon, France).

Consent to Participate

Parental written informed consent was provided for inclusion of clinical data and samples in the study.

Consent for Publication

Written informed consent for publishing the results of this study considering ethical confidentiality and anonymity was obtained from the parents.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 57 KB)

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tusseau, M., Lovšin, E., Samaille, C. et al. DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling. J Clin Immunol 42, 1310–1320 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: